Printer Friendly

Clinical trial finds KoACT to benefit bone strength.

Results from a double-blind, placebo-controlled clinical trial on KoACT, a patented collagen compound from AIDP, have been published in the Journal of Food and Nutritional Disorders. This trial at Florida State University in Tallahassee found that KoACT may have the potential to reverse bone loss in osteopenic postmenopausal women.

In this trial, 40 women, 1 to 5 years postmenopausal, were randomized to one of two treatment groups to receive daily for three months either calcium (control) or KoACT. Bone mineral density of lumbar spine and total body were assessed at baseline and at three months using dual-energy X-ray absorptiometry. Blood was collected at baseline and three months to assess biomarkers of bone metabolism. KoACT significantly increased total body bone mineral density when compared to the control group (P<0.05). A significant increase (P<0.05) in the BAP/TRAP5b ratio percent change was indicated for the KoACT group. Bone specific alkaline phosphatase (BAP) is a biochemical marker for bone formation, while TRAP5b are usually associated with bone resorption. Ratio BAP/TRAP5b indicates the balance between bone regeneration versus bone loss. Collectively, these preliminary data suggested that KoACT enhances bone mass potentially by shifting favorably the balance of bone formation versus bone resorption in the process of bone turnover. For more information:
COPYRIGHT 2013 Rodman Publishing
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2013 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Title Annotation:Research Highlights
Publication:Nutraceuticals World
Date:May 1, 2013
Previous Article:Cognizin citicoline may improve mild cognitive impairment.
Next Article:Study shows stress-reducing benefits of Ashwagandha.

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters